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Abstract 
A comparative investigation was undertaken on 1‐–2 mm sized granules of two forms of synthetic 
bone graft substitute (SBG) with identical pore structure but varied bulk chemistry, stoichiometric 
hydroxyapatite (HA) and silicate substituted (0.8 wt% Si) hydroxyapatite (SA), to assess the influence 
of SBG chemistry on the relative affinity of an osteogenic growth factor (GF), recombinant human 
bone morphogenetic protein-2 (rhBMP-2). A previously described novel fluorescent probe, 
fluoresceinthioureidoaminocaproic acid (FTCA), was covalently attached to rhBMP-2 to give FTCA-
rhBMP-2 and facilitate the quantitative monitoring of GF uptake and release from the two 
chemistries of SBG. The relative affinity of rhBMP-2 for the HA and SA granules was assessed at a 
physiologically relevant concentration of 300 ng mL‐− 1 from three (increasingly complex) 
environments; phosphate buffered saline (PBS), minimum Eagles’' medium (MEM) and serum 
supplemented MEM (SCEM) in order to closely mimic clinical bone repair procedures. The results 
demonstrated that rhBMP-2 affinity to SBGs 
was highly sensitive to both SBG chemistry and the composition of the local environment. Under the 
most physiologically relevant competitive conditions of SCEM, rhBMP-2 showed greater affinity to 
SA (P < 0.05) such that 50% of the rhBMP-2 in solution was adsorbed to the SA granules after only 15 
minutesmin, as compared to 30% adsorbed to the HA granules. Subsequent investigation of the 
desorption of adsorbed GF from the SBGs demonstrated that a significantly higher percentage of the 
adsorbed rhBMP-2 was desorbed from HA as compared to SA granules. Together, these observations 
suggested that at physiologically relevant concentrations and conditions, rhBMP-2 has a greater 
affinity to silicate-substituted hydroxyapatite as compared to stoichiometric hydroxyapatite, which 
may in part explain the enhanced osteoconductivity and reported osteoinductivity for silicate-
substituted hydroxyapatite based SBGs. 
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1 Introduction 
The competitive nature of protein adsorption has been of interest within the biomaterials 
community and the orthobiologics industries, as understanding or control of protein adsorption and 
structural or conformational dependence of protein activity is key to the performance of many 
classes of biomedical device, while more recently the kinetics of protein adsorption and desorption 
have proved critical to the design of suitable drug delivery vehicles. In the orthopaedic field this is 
particularly relevant when considering synthetic bone graft substitutes (SBG). SBGs are used to 
replace or repair diseased or damaged bone tissue due to trauma or degenerative disease such as 
osteoporosis, which has become of increasing socio-economic importance due to pressures on the 
healthcare industry resulting from the aging population and greater expectations regarding quality 
of life [1]. Shortage of donors and side effects remain a challenge leading to further research into 
approaches in tissue engineering that involves the seeding of porous biocompatible and/or 
biodegradable scaffolds. Understanding the nature of these scaffolds is of paramount importance, 
especially now, when they are no longer expected to act as passive structural matrices capable of 
supporting cell adhesion/proliferation, protein adsorption and such but also act as 3D carriers for 
the delivery of bioactive molecules to enhance tissue regeneration. [1–3]. In this study, we thus 
concentrated on looking into understanding and monitoring the effect of protein adsorption on our 




different techniques and on various biomaterials, all showed that the competitive nature of proteins 
is strongly influenced by the protein concentration [4] affinity to the biomaterial surface [5] and time 
[6], where a temporal dependence can manifest itself as the “Vroman” effect, where small highly 
mobile proteins that may initially colonize a surface are gradually replaced by less mobile proteins 
with a greater affinity for the surface. It is well recognised that pore size and pore connectivity play 
an important role [7], however, in this instance, the focus is mainly on monitoring and 
understanding the protein adsorption behaviour observed from our scaffold in a competitive 
environment. The presence of secondary protein species has also been shown to affect adsorption 
of a primary protein through influence on conformational change of the primary species [8]. 
Recently, we developed a novel methodology to covalently attach a novel fluorescent probe to a 
target protein and validated the ability of the probe to monitor both the adsorption and desorption 
of the target protein species from a variety of environments [9]. This was in response to studies 
conducted within our laboratories on silicate substituted hydroxyapatite (0.8 wt% Si, SA) and 
stoichiometric hydroxyapatite (HA) which demonstrated that on introduction into a physiological 
environment apatite based synthetic bone graft substitute (SBG) materials undergo specific patterns 
of ionic and proteomic exchange with local physiological fluids that are sensitive to the precise 
chemistry of the SBG. Moreover we identified that variation in the sequestering of specific adhesion 
proteins, such as fibronectin and vitronectin subsequently appeared to direct the behaviour of 
osteogenic cells [10–15]. 
This is particularly interesting as studies conducted in vivo with hydroxyapatite based porous SBG 
scaffolds with matched pore structures but relatively small variations in chemistry (ranging from 0‐ 
to 1,5 wt% Si substitution) have demonstrated optimal bone regeneration at a level of 0.8 wt% 
silicate substitution, including accelerated vascularisation, an increase in the rate of early bone 
formation and elevated levels in the equilibrium volume of new bone formed [16–19] Moreover, 
studies using an ectopic animal model demonstrated that SA SBG porous granules behaved like an 
osteoinductive autograft with the observation of spontaneous mesenchymal and endochondral 
bone formation within the ectopically placed grafts, suggesting multiplicity in the mechanisms of 
bone formation supported by these grafts. More recently, De Santis et al. found that in vivo, a 
hydroxyapatite substituted with Iron (Fe-HA) showed greater cell growth leading to improved bone 
regeneration as compared to stoichiometric HA [20], further highlighting the complexity and 
sensitivity of protein adsorption and subsequent biological response to chemical modification of SBG 
scaffolds. 
We hypothesised that there may be a chemotactic dependence on this behaviour with optimal bulk 
chemistries relating to optimal surface physico-chemistries that sequester and enrich key adhesion 
proteins, angiogenic and osteogenic growth factors to confer apparent osteoinductive behaviour on 
the synthetic scaffolds. Thus, the development of a tool to facilitate the tracking of the interactions 
between a single species of protein and a ‘real’ non- idealised SBG surface under a range of 
environments was key to testing this theory through the investigation of the affinity between the 
‘optimal’ formulation of 0.8 wt% Si SA and stoichiometric HA. 
Bone morphogenic protein-2 (BMP-2) is a powerful growth factor (GF) involved in the process of 
osteogenesis. It plays a central role in osteogenic cell recruitment, proliferation and differentiation 
and has FDA approval for use in specific clinical indications, including treatment of open fractures of 
long bones, non-unions and spinal fusion, to aid bone regeneration and repair. It has been critically 
assessed as a mediator of bone induction, often used in conjunction with injectable hydrogels or 
hydrogel-nanoparticle combinations [21] for improved bone formation in various studies across the 
field [22–24]. It was discovered in 1965 by Urist to induce bone formation when purified from 
decalcified bone [25–26] and then further investigated as a member of the transforming growth 
factor-β (TGF-β) superfamily [27]. Its role as a regulator of new bone formation appears to be tied to 
its ability to act both morphologically and mitogenically and thus play a critical role in mesenchymal 
stem cell proliferation and differentiation. [28,29–31]. However, there are concerns associated with 
clinical complications related to the use of supra-physiological doses of BMP-2 as opposed to SBGs 
[32–33]. Moreover, there is evidence that in SBGs with highly osteoconductive or osteogenic 
characteristics the regulation of BMP-2 expression is key, where studies by Jenis et al. [17] into the 
temporal pattern of BMP-2 gene expression within tissue harvested from the central and peripheral 
aspects of fusion masses after postereolateral lumbar fusion on adult New Zealand white rabbits, 
demonstrated no significant variation in the expression pattern of BMP-2 throughout fusion masses 
treated with either SA or the gold standard, autograft but elevated expression of collagen I, and a 
greater peak expression of collagen II in the central zones of SA treated fusions. Suggesting that 
there is some modification of the pattern of gene expression within the bone formation cascade 
when exposed to SA, where SA stimulates equivalent or earlier expression of bone formation 
markers as compared to treatment with autograft [17]. Therefore this paper, details the 
investigation of the adsorption and desorption behaviour of rhBMP-2 at a physiologically active 
concentration of 300 ng mL‐− 1 [34–35] under a series of increasingly complex environmental 
conditions at 37 °C to investigate the sensitivity of these processes to SBG chemistry and the local 
environment to test the hypothesis that the bioactivity, and apparent osteoinductive behaviour 
reported for SA SBG [36–37] may have a chemotactic dependence. 
 
2 Materials and methods 
All chemicals and reagents for the synthesis of the ceramic samples were obtained from VWR. 
Hydroxyapatite powders were produced via an aqueous precipitation route as previously described 
by Gibson et al. [38] and porous granules were synthesised via a novel slip foaming technique. 
Recombinant human bone morphogenetic protein-2 (rhBMP-2) was purchased from Sera 
Laboratories (UK), phosphate buffer solution (PBS), minimum Eagles’' medium (MEM), foetal bovine 
serum (FBS) and dialysis tubes were obtained from Sigma-Aldrich. 
 
2.1 Labelling of protein species and test media 
Labelling of the rhBMP-2 with FTCA and the preparation of FTCA-rhBMP-2 standards were made as 
previously described by Mafina et al. [9]. Experiments were conducted in 3 test media, (i) phosphate 
buffer solution (PBS), (ii) minimum Eagles’' medium (MEM) and (iii) MEM supplemented with 10% 
foetal bovine serum (SCEM), so as to closely mimic clinical bone repair studies; where proteins are 
often prepare at room temperature with a particular medical device, then implanted in physiological 
defects at 37o °C. 
 
2.2 Adsorption and desorption protocol 
1.5 mL of FTCA-rhBMP-2 protein solution, at a concentration of 300 ng mL‐− 1, was placed in 
triplicate in clean glass vials containing 0.5 g of porous granules per vial. To analyse the adsorption, 
100 μL aliquots of the protein solution were removed at time intervals of 1, 5, 10 and 15  min. After 
15  min, the porous granules were removed, and placed in a second clean glass vial containing 1.5 
mL of fresh test media and gently agitated for 
30 secondss to remove any loosely bound FTCA-rhBMP-2. The porous granules were then removed 
and placed in a third clean glass vial also containing 1.5 mL of fresh test media to analyse desorption, 
which was performed through removal of aliquots of 100 μL at time intervals of 5, 60, 240 and 1440 
min after the addition of the granules to the test media. For validation the test media used to wash 
the loosely bound protein was also analysed. 
Using the procedures previously established [39] appropriate volumes of both adsorption and 
desorption samples containing unknown concentrations of labelled BMP-2 were pipetted in 
triplicate and repeated, so n = 6, into a 96-well plate and the appropriate test media added to make 
a final volume of 200 μL per well. Low and high concentration standard dilution series were run on 
each plate to prepare calibration curves as shown in Figure.  1. Fluorescence intensity of the 
unknowns and standards were measured using a fluorescence spectrometer (Galaxy, UK) with 
excitation and emission wavelengths set at 494 and 520 nm, respectively. 
 
 
Fig. 1 Calibration curves for the (a) high and (b) low range FTCA-rhBMP-2 dilution series. 
 
2.3 Statistical analysis 
The Krusal-Wallis (KW) test was used for statistical analysis between treatment groups (media type 
or specimens) and to compare within the same treatment group at different time points the 
Wilcoxon-Mann-Whitney (WMW) was used, where for both p values of less than < 0.05 were 
considered statistically significant (KaleidaGraph, v8.0 Synergy software). 
 
3 Results 
FTCA-rhBMP-2 adsorption (uptake) processes 
  
Figure. 2(a) shows a distinct variation in the adsorption behaviour of FTCA-rhBMP-2 to HA granules 
as the test media was varied. In PBS a plateau was not reached by the end of adsorption experiment, 
whereas with both MEM and SCEM FTCA-rhBMP-2 adsorption reached a maximum relatively quickly 
(after only 1 min) and maintained this level of adsorption throughout the length of the experiment. 
However, adsorption from MEM and SCEM differed in the maximal amounts of growth factor 
adsorbed on HA, with significantly more FTCA-rhBMP-2 (138.5 ± 7.5 ng mL‐− 1, p < 0.01) adsorbed 




Fig. 2 Absolute amounts of the FTCA-rhBMP-2 adsorbed onto (a) HAG and (b) SAG in PBS, MEM and 
in SCEM at 37 o°C (n = 6 ± std.; *** corresponds to p value of < 0.005; NS denotes Not Significant). 
 
Figure. 2(b) also shows a distinct variation in the adsorption behaviour of FTCA-rhBMP-2 to SA 
granules as the test media was varied. Similarly to HA, a plateau was not reached by the end of the 
adsorption experiment in PBS, although a significantly higher level of growth factor was adsorbed 
onto the SA as compared to the HA (175.2 ± 2.8 ng mL‐− 1, p < 0.01). In MEM, the pattern of BMP-2 
adsorption to SA was similar to HA, reaching a maximum after only 1 min of incubation. However, 
unlike the behaviour observed with HA, the maximum level of BMP-2 adsorption from SCEM to SA 
was not attained until after 10  min of incubation, and for SA there was no significant difference 
between the maximal level of FTCA-rhBMP-2 adsorbed from either MEM or SCEM (respectively 
142.4 ± 7.1 or 148.9 ± 3.3 ng mL‐− 1; NS). 
 
This variation in BMP-2 adsorption behaviour from the most physiologically relevant environment 
(SCEM) is highlighted in Figure. 3, which shows significant variation in the adsorption behaviour of 
BMP-2 to HA and SA SBG. On HA, 30% of the FTCA-rhBMP-2 in solution was rapidly adsorbed to the 
granules within the first minute followed by a net loss in the level of adsorbed BMP-2 to 18% at 5 
min and then no subsequent variation for the rest of the experiment. In contrast by 1 and 5 min only 
10% and 15% respectively, of the BMP-2 had adsorbed to the SA granules from SCEM. However by 
10 min this level had increased significantly to 50% of the BMP-2, with no significant variation for the 




Fig. 3 Relative percentage of FTCA-rhBMP-2 adsorbed onto HAG (labelled green) and SAG (labelled 
purple) in SCEM at 37 o°C (n = 6 ± std.; *** corresponds to p value of < 0.005). 
 
3.2 FTCA-rhBMP-2 desorption (release) process 
 
Fig. 4 shows the results of the desorption experiments, conducted over a period of 24 h, 





Fig.4 Desorption patterns of the FTCA-rhBMP-2 desorbed from (a) HAG and (b) SAG in PBS, MEM and 
in SCEM at 37 o°C (n = 6 ± std.; *** corresponds to p value of < 0.005). 
 
On incubation in either of the serum free environments, (PBS or MEM), a significant quantity of 
BMP-2 was desorbed from both the HA and SA SBG within the first 5 min of incubation, after which a 
dynamic equilibrium appears to have become established between the rhBMP-2 desorbed into the 
media and the BMP-2 pre-adsorbed on the granules. The absolute quantity of BMP-2 desorbed from 
HA SBG was in general greater than that desorbed from SA SBG, particularly relevant when one 
considers that there was a greater quantity of BMP-2 initially adsorbed to the SA granules, with 
BMP-2 desorption from SA showing less sensitivity to the nature of the serum-free environment 
  
and BMP-2 desorption in MEM showing less sensitivity to the SBG’'s chemistry (in terms of absolute 
quantity of BMP-2 desorbed). 
 
Incubation in the protein containing environment (SCEM) demonstrated that desorption of rhBMP-2 
appeared to be significantly enhanced by the presence of the “competing” proteins in solution from 
both HA and SA SBG, and initially (after 5 min) the absolute levels of BMP-2 released from the HA 
and SA granules were very similar. However, the pattern and relative percentage of protein 
desorption was highly chemistry sensitive as shown in Figure. 5 which compares the relative 




Fig. 5 Release patterns of the FTCA-rhBMP-2 desorbed from HAG (labelled green) and SAG (labelled 
purple) in SCEM as a percentage adsorbed at 37 o°C (n = 6 ± std.; *** corresponds to p value of < 
0.005). 
 
Within the first 5 min of incubation in SCEM; 55 % of the BMP-2 adsorbed onto HA granules was 
desorbed with no significant further release over 24 h. In contrast, only 30 % of the BMP-2 was 




The aim of this study was to investigate the relative affinity of an osteogenic growth factor (GF), 
recombinant human bone morphogenetic protein-2 (rhBMP-2) for porous stoichiometric 
hydroxyapatite (HA) and silicate substituted hydroxyapatite (SA) synthetic bone graft (SBG) 
substitute granules from a series of increasingly complex environments. Our objective was to 
confirm or refute our hypothesis that one mechanism of action by which SA SBG may enhance new 
bone formation in vivo is via modification of the osteogenic response through the enrichment of key 
adhesion proteins and growth factors that combine to recruit both pre-committed osteogenic and 
stem cells and direct their differentiation down an osteogenic pathway. 
More recently studies using an osteoinductive animal model to assess the combined effect of 
increasing strut porosity and altering graft chemistry demonstrated a synergistic relationship 
between silicate substitution and strut microporosity [36–37,40]. This has led to interest in the 
combined effect of these parameters on both protein adsorption [39,41] and ion release [42]. 
Investigation of protein adsorption has identified that graft chemistry affects both affinity and 
confirmation while ion release has recently been determined to vary significantly with strut porosity 
in SBG suggesting that chemotactic, biomechanical and biochemical cues combine to mediate 
osteoconduction and osteoinduction by multiple pathways. 
No plateau of FTCA-rhBMP-2 adsorption was observed on SA or HA SBG in PBS, suggesting that the 
medium’'s chemistry and interactions with BMP-2 did not have a pronounced effect on the 
mechanisms of the growth factor’'s adsorption as compared to the SBG’'s chemistry. Differences 
observed between the tests were defined by the maximal amounts adsorbed, found to be higher on 
the silicate bone graft substitute as compared to the stoichiometric bone graft (see Figure. 2a & b, 
the blue lines). The patterns observed in MEM as compared to PBS for both SBG clearly suggest an 
influence of this medium’'s more complex chemistry on the affinity of the growth factor, as maximal 
adsorption occurred within the first minute and plateaued throughout the remainder of the 
experiment with no significant difference between the maximal adsorbed amounts on HA or SA 
SBGs. In this environment, FTCA-BMP-2 adsorption appeared to be more sensitive to medium 
interactions, irrespective of the chemistry of the SA or HA SBG (see Figure. 2a & b, the red lines). 
In contrast, in the most complex environment, consisting of MEM supplemented with 10% foetal 
bovine serum, the observed FTCA-BMP-2 patterns of adsorption were significantly different between 
SA and HA SBG. On HA SBG, the pattern closely mimics that of the adsorption observed in MEM, 
suggesting a mechanism where the medium’'s chemistry still dominated behaviour. Furthermore, 
the presence of serum proteins appear to have inhibited FTCA- BMP-2 adsorption to HA SBG, with 
only 70 ng mL‐− 1 adsorbed from SCEM compared to twice as much adsorbed to HA SBG from MEM. 
It has been previously discussed that the amino acid components of MEM have a strong affinity 
  
with rhBMP-2 to enhance adsorption [43], which was also observed for BSA [9]. In the absence of 
serum protein this was also observed in the present study for both HA and SA SBG. However, the 
addition of serum proteins in solution was observed to inhibit the effect of MEM enhancement on 
rhBMP-2 adsorption to HA SBG. This implies that the dynamic adsorption behaviour of the growth 
factor is more driven by a protein-protein interaction than a protein-surface interaction for HA, as 
compared to BSA where both of these combinations were important. Support for this hypothesis 
exists through the work of Uludag et al. who suggested that an increase in the protein isoelectric 
point (pI) in solution due to the presence of additional smaller proteins, may result in a higher 
retention of the growth factor in solution [44]. They further proposed that charges on the growth 
factor were neutralised with sodium ions to limit the BMP-2 interactions with the HA surface and 
allowed reversible formation of water-bridged H-bonds that changed the protein conformation. 
However, in this work, the charges were not neutralised, suggesting they may have been free to 
interact with ions and amino acids present in solution, before interacting with the biomaterial’'s 
surfaces, to thus affect the growth factor’'s conformation, as in agreement with Dong et al. [43]. This 
change in protein conformation or morphology was also considered in the work of Guth et al. as the 
proposed mechanism behind variation in cell attachment to surfaces with ostensibly the same 
quantity of adsorbed protein [39,41]. 
For SA SBG, the pattern of growth factor adsorption from SCEM closely resembled that observed in 
PBS, suggesting its mechanism to be synergistically influenced by the bone graft substitute’'s 
chemistry and the medium’'s chemistry (see Figure. 2 a & b, the green lines). As a result in SCEM, 
significantly more FTCA-BMP-2 was adsorbed on SA SBG as compared to HA SBG as shown in Figure. 
3. 
The desorption behaviour (see Figure. 4) closely reflected the findings of the adsorption 
experiments, with FTCA-BMP-2 desorption being primarily influenced by SBG chemistry in PBS, the 
medium’'s chemistry in MEM, with a synergistic influence observed in SCEM (Figure. 5). These 
observations further validated the point that the affinity of rhBMP-2 to a particular SBG depends on 
both the local medium environment and the surface chemistry of the SBG. 
In summary, this study clearly showed not only the importance of the scaffolds surface chemistry on 
the affinity of FTCA-rhBMP-2 to bone graft substitute scaffold materials, but also the influence of the 
chemistry of the local physiological environment on its adsorption behaviour. The BMP adsorption 
behaviours with the biomaterials in the different mediums are different. For HAG, additional protein 
inhibited the BMP binding; but for SAG, additional protein did not affect the final adsorption 
quantity. It also demonstrated that, by using a physiologically relevant concentration of rhBMP-2 
labelled with a novel fluorescent probe, silicate substituted hydroxyapatite has a greater affinity for 
rh-BMP-2 than stoichiometric hydroxyapatite under competitive conditions. This finding supports 
our hypothesis that there may be a chemotactic dependence behind the enhanced 
osteoconductivity observed for specific bulk chemistries of bone graft substitute material, relating to 
these grafts possessing surface physico-chemistries that sequester and enrich key adhesion proteins, 





The binding affinity of rhBMP-2 for porous silicate substituted and a stoichiometric hydroxyapatite 
synthetic bone graft granule was investigated from a series of increasingly complicated 
environments. Both the composition of the local physiological environment and the chemistry of the 
synthetic bone graft granules were found to impact on rhBMP-2 adsorption and desorption. 
Under the most physiologically relevant competitive conditions of 10% serum supplemented 
minimum Eagles medium, silicate substituted hydroxyapatite was found to possess a greater affinity 
for rhBMP-2 than stoichiometric hydroxyapatite. These observations support the hypothesis that the 
enhanced bioactivity of these grafts materials may in part be related to their ability to sequester and 
enrich key adhesion proteins, angiogenic and osteogenic growth factors to confer apparent 
















fluoresceinthioureidoaminocaproic  acid  
 
PBS 
phosphate buffered saline  
 
MEM 
minimum Eagles essential medium  
 
SCEM 
serum complete Eagles medium  
 
rhBMP-2 
recombinant human bone morphogenetic protein-2  
 
FBS 
foetal bovine serum 
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• describes the use of a fluorescent label covalently attached to a growth factor (RhBMP-2) to 
monitor adsorption and desorption behaviour of the protein on medical devices in a competitive 
environment. 
 
• The binding affinity of rhBMP-2 for porous silicate substituted and a stoichiometric 
hydroxyapatite synthetic bone graft granule was investigated from a series of increasingly 
complicated environments. 
 
• Rh-BMP-2 at a physiologically relevant concentration of 300 ngmL-1 was tested in three 
(increasingly complex) environments; phosphate buffered saline (PBS), minimum Eagles’ medium 
(MEM) and serum supplemented MEM (SCEM)  in order to closely mimic clinical bone repair 
procedures 
• observations support the hypothesis that the enhanced bioactivity of these grafts materials 
may in part be related to their ability to sequester and enrich key adhesion proteins, angiogenic and 
osteogenic growth factors to confer apparent osteoinductive behaviour on the synthetic scaffolds. 
 
